Sort
15,273 grants matching “antimicrobial resistance”
Anti-MRSA activity of a Bacillus pumilus natural isolate
$192,500Michiko M Nakano · Oregon Health & Science University · R21 · FY2010 · AI
Reducing excess broad-spectrum antibiotic use in gonorrhea
$192,500Jeffrey David Klausner · University Of California Los Angeles · R21 · FY2016 · AI
Novel Strategies for Treating Biofilm-Forming Pathogens with Phage Therapy
$192,500John Joseph Dennehy · Queens College · R21 · FY2022 · AI
Lasso Peptide Discovery
$192,500Aaron James Link · Princeton University · R01 · FY2016 · GM
The amyloid precursor protein protects against acute lung injury
$192,500Jonathon Peter Audia · University Of South Alabama · R21 · FY2024 · AI
Protease - protease inhibitor system of Tannerella forsythia
$192,500Jan S Potempa · University Of Louisville · R21 · FY2017 · DE
Defining the role of host lipid repertoire in Mycobacterium tuberculosis infection
$192,500Fikadu G. Tafesse · Oregon Health & Science University · R21 · FY2017 · AI
Elucidating the genotypic determinants and phenotypic effects of polymyxin resistance in Klebsiella pneumoniae utilizing CRISPR-Cas9
$192,456Thomas Howe McConville · Columbia University Health Sciences · K08 · FY2023 · AI
Elucidating the genotypic determinants and phenotypic effects of polymyxin resistance in Klebsiella pneumoniae utilizing CRISPR-Cas9
$192,456Thomas Howe McConville · Columbia University Health Sciences · K08 · FY2020 · AI
Elucidating the genotypic determinants and phenotypic effects of polymyxin resistance in Klebsiella pneumoniae utilizing CRISPR-Cas9
$192,456Thomas Howe McConville · Columbia University Health Sciences · K08 · FY2022 · AI
Elucidating the genotypic determinants and phenotypic effects of polymyxin resistance in Klebsiella pneumoniae utilizing CRISPR-Cas9
$192,456Thomas Howe McConville · Columbia University Health Sciences · K08 · FY2021 · AI
Elucidating the genotypic determinants and phenotypic effects of polymyxin resistance in Klebsiella pneumoniae utilizing CRISPR-Cas9
$192,456Thomas Howe McConville · Columbia University Health Sciences · K08 · FY2024 · AI
Activation of Alginate Genes in Pseudomonas aeruginosa
$192,418Dennis Edward Ohman · Virginia Commonwealth University · R01 · FY2007 · AI
First-in-class rationally designed inhibitors of the SUF-like pathway of iron-sulfur cluster biosynthesis for treating infections caused by S. aureus and other Gram-positive bacteria
$192,277Richard C Holz · Colorado School Of Mines · R21 · FY2024 · AI
The development & pilot implementation of a Cas13a-based low-cost point-of-care assay for detecting Neisseria gonorrhoeae and molecular markers of antimicrobial resistance in resource-limited settings
$192,137Lao-Tzu Allan-Blitz · Brigham And Women'S Hospital · K23 · FY2025 · AI
Biofilm Growth on Functionalized Surfaces
$192,071Jun F Liang · The Trustees Of The Stevens Institute Of Technology · R21 · FY2010 · AI
Defining resistance and tolerance mechanisms in hyper-susceptible mice during M. tuberculosis infection
$191,999Andrew Olive · Michigan State University · R21 · FY2020 · AI
Desiccation resistance in Coxiella burnetii
$191,932Howard A Shuman · University Of Chicago · R21 · FY2014 · AI
Commensal microbes and sexual dimorphism in autoimmunity
$191,932Alexander V Chervonsky · University Of Chicago · R21 · FY2014 · AI
Development of a prototype Klebsiella O polysaccharide conjugate vaccine
$191,875Alan S Cross · University Of Maryland Baltimore · R21 · FY2016 · AI
Molecular Basis of Human Defensins as Novel Lipid II Binding Peptide Antibiotics
$191,875Erik De Leeuw · University Of Maryland Baltimore · R21 · FY2012 · AI
Targeting polymicrobial infections of diabetic foot ulcers with a novel antimicrobial peptide therapy
$191,875Dragana Ajdic · University Of Miami School Of Medicine · R21 · FY2021 · AI
Optogenetic Control of Bacterial Persistence to Study Biomaterial Infections
$191,850Dacheng Ren · Syracuse University · R21 · FY2025 · AI
Advancing pharmacy-based delivery of primary STI and HIV prevention for cisgender women
$191,846Jillian Pintye · University Of Washington · R01 · FY2025 · HD
Molecular Archaeology: Vintage Beta Lactams for Resistant Gram Negative Infectio
$191,798Scott J. Hecker · Rempex Pharmaceuticals, Inc. · R21 · FY2013 · AI